Literature DB >> 29889515

Targeting Protumoral Tumor-Associated Macrophages with Nanobody-Functionalized Nanogels through Strain Promoted Azide Alkyne Cycloaddition Ligation.

Lutz Nuhn1,2,3, Evangelia Bolli4,5, Sam Massa4,5, Isabel Vandenberghe6, Kiavash Movahedi4,5, Bart Devreese6, Jo A Van Ginderachter4,5, Bruno G De Geest1,2.   

Abstract

Tumor-associated macrophages (TAMs) with high expression levels of the Macrophage Mannose Receptor (MMR, CD206) exhibit a strong angiogenic and immune suppressive activity. Thus, they are a highly attractive target in cancer immunotherapy, with the aim to modulate their protumoral behavior. Here, we introduce polymer nanogels as potential drug nanocarriers which were site-specifically decorated with a Nanobody (Nb) specific for the MMR. Using azide-functionalized RAFT chain transfer agents, they provide access to amphiphilic reactive ester block copolymers that self-assemble into micelles and are afterwards core-cross-linked toward fully hydrophilic nanogels with terminal azide groups on their surface. MMR-targeting Nb can site-selectively be functionalized with one single cyclooctyne moiety by maleimide-cysteine chemistry under mildly reducing conditions which enables successful chemoorthogonal conjugation to the nanogels. The resulting Nb-functionalized nanogels were highly efficient in targeting MMR-expressing cells and TAMs both in vitro and in vivo. We believe that these findings pave the road for targeted eradication or modulation of pro-tumoral MMRhigh TAMs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29889515     DOI: 10.1021/acs.bioconjchem.8b00319

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  10 in total

Review 1.  Progress on Modulating Tumor-Associated Macrophages with Biomaterials.

Authors:  Meilyn Sylvestre; Courtney A Crane; Suzie H Pun
Journal:  Adv Mater       Date:  2019-09-27       Impact factor: 30.849

2.  Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.

Authors:  Evangelia Bolli; Maximilian Scherger; Sana M Arnouk; Ana Rita Pombo Antunes; David Straßburger; Moritz Urschbach; Judith Stickdorn; Karen De Vlaminck; Kiavash Movahedi; Hans Joachim Räder; Sophie Hernot; Pol Besenius; Jo A Van Ginderachter; Lutz Nuhn
Journal:  Adv Sci (Weinh)       Date:  2021-03-08       Impact factor: 16.806

Review 3.  Theranostics in immuno-oncology using nanobody derivatives.

Authors:  Quentin Lecocq; Yannick De Vlaeminck; Heleen Hanssens; Matthias D'Huyvetter; Geert Raes; Cleo Goyvaerts; Marleen Keyaerts; Nick Devoogdt; Karine Breckpot
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

Review 4.  Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery.

Authors:  Natalie Fuchs; Mergim Meta; Detlef Schuppan; Lutz Nuhn; Tanja Schirmeister
Journal:  Cells       Date:  2020-09-02       Impact factor: 6.600

Review 5.  Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy.

Authors:  Emile J Clappaert; Aleksandar Murgaski; Helena Van Damme; Mate Kiss; Damya Laoui
Journal:  Front Immunol       Date:  2018-10-08       Impact factor: 7.561

Review 6.  Recombinant expression of nanobodies and nanobody-derived immunoreagents.

Authors:  Ario de Marco
Journal:  Protein Expr Purif       Date:  2020-04-11       Impact factor: 1.650

7.  CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy.

Authors:  Jan David Beck; Matthias Birtel; Erik Haefner; Isabell Sofia Keil; Daniel Reidenbach; Nadja Salomon; Ikra Gizem Yildiz; Mustafa Diken
Journal:  Hum Vaccin Immunother       Date:  2019-11-11       Impact factor: 3.452

8.  Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels.

Authors:  Maximilian Scherger; Evangelia Bolli; Ana Rita Pombo Antunes; Sana Arnouk; Judith Stickdorn; Alexandra Van Driessche; Hansjörg Schild; Stephan Grabbe; Bruno G De Geest; Jo A Van Ginderachter; Lutz Nuhn
Journal:  Cells       Date:  2020-10-01       Impact factor: 6.600

9.  A Polylactide-Based Micellar Adjuvant Improves the Intensity and Quality of Immune Response.

Authors:  Myriam Lamrayah; Capucine Phelip; Céline Coiffier; Céline Lacroix; Thibaut Willemin; Thomas Trimaille; Bernard Verrier
Journal:  Pharmaceutics       Date:  2022-01-03       Impact factor: 6.321

10.  Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors.

Authors:  Judith Stickdorn; Lara Stein; Danielle Arnold-Schild; Jennifer Hahlbrock; Carolina Medina-Montano; Joschka Bartneck; Tanja Ziß; Evelyn Montermann; Cinja Kappel; Dominika Hobernik; Maximilian Haist; Hajime Yurugi; Marco Raabe; Andreas Best; Krishnaraj Rajalingam; Markus P Radsak; Sunil A David; Kaloian Koynov; Matthias Bros; Stephan Grabbe; Hansjörg Schild; Lutz Nuhn
Journal:  ACS Nano       Date:  2022-02-01       Impact factor: 15.881

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.